Poor
Not Aligned
Patient Risk:
High
Summary
Most claims about atorvastatin–warfarin interaction, INR changes/monitoring schedules, and relative statin interaction strengths are not supported by the provided Lipitor label excerpts. Some general statements about statin–CYP3A4 inhibitor risk and use with caution are partially alignable, but the majority of specific numeric and management claims cannot be verified from the supplied label text.
Category Scores
Accurate Statements
Atorvastatin should be used with warfarin only if benefits outweigh risks.
Not directly supported: the provided excerpts do not include warfarin-specific benefit/risk language. However, the label excerpted drug-interaction section emphasizes increased myopathy risk with certain interacting drugs and recommends caution with high-dose CYP3A4 inhibitors; a generic “use only if benefits outweigh risks” cannot be directly mapped to warfarin from provided text.
Unsupported Statements
Lipitor (atorvastatin) interacts with warfarin.
No warfarin-specific interaction information is present in the provided label excerpts (Drug Interactions 7 lists strong CYP3A4 inhibitors, grapefruit juice, and cyclosporine).
The combination of atorvastatin and warfarin raises warfarin blood levels.
No warfarin pharmacokinetic effect statements are present in provided excerpts.
Raising warfarin blood levels increases bleeding risk due to CYP3A4 enzyme inhibition by atorvastatin.
No warfarin-bleeding risk mechanism related to CYP3A4 inhibition by atorvastatin is present in provided excerpts.
Atorvastatin moderately inhibits CYP3A4 and CYP2C9 enzymes that metabolize warfarin.
No CYP3A4/CYP2C9 inhibition statements for atorvastatin are present in provided excerpts.
Atorvastatin prolongs warfarin's effects.
No warfarin effect/prolongation information is present.
Atorvastatin elevates INR (a measure of blood clotting time) when used with warfarin.
No INR or warfarin monitoring/effects are present in provided excerpts.
Studies show average INR increases of 1.0–1.6 points in patients starting Lipitor while on warfarin.
No INR numeric study data in provided excerpts.
The effects on INR appear within days after starting Lipitor in patients taking warfarin.
No timing data related to warfarin/INR are present.
American College of Cardiology guidance and the FDA label for the drugs state to use them together only if benefits outweigh risks.
The provided label excerpts do not mention warfarin/atorvastatin combined use or any ACC/FDA guidance statements.
American College of Cardiology guidance and the FDA label state that INR should be monitored frequently when using atorvastatin with warfarin.
No INR/warfarin monitoring guidance is present in the provided label excerpts.
One example monitoring schedule stated is weekly INR checks at the start, then every 4–6 weeks once stable.
No monitoring schedule is present in the provided label excerpts.
The target INR for most patients is 2.0–3.0.
No INR target ranges are present in the provided label excerpts.
An INR above 4.0 signals high bleeding risk.
No INR threshold/bleeding interpretation is present in provided excerpts.
Case reports link the combination of atorvastatin and warfarin to major bleeding such as GI hemorrhage in 1–5% of cases without monitoring.
No atorvastatin/warfarin bleeding incidence or “1–5%” case-report claim is present.
Pravastatin has minimal interaction with warfarin and is preferred for lowest risk.
The provided label excerpts do not compare statins or discuss warfarin interaction differences among specific statins.
Rosuvastatin (Crestor) has minimal interaction with warfarin.
No rosuvastatin/warfarin interaction comparison is present.
Pravastatin or rosuvastatin are often used to replace Lipitor in patients taking warfarin.
No label excerpts discuss replacing atorvastatin with other statins in warfarin-treated patients.
Simvastatin (Zocor) has moderate-high interaction strength with warfarin.
No simvastatin/warfarin interaction comparison is present.
Lovastatin has moderate-high interaction strength with warfarin similar to simvastatin.
No lovastatin/warfarin interaction comparison is present.
Fluvastatin has low interaction strength with warfarin.
No fluvastatin/warfarin interaction comparison is present.
Pitavastatin has minimal interaction with warfarin and the lowest interaction risk.
No pitavastatin/warfarin interaction comparison is present.
One suggested management approach is to check INR 3–7 days after starting Lipitor, then regularly.
No INR/warfarin management timing is present in provided excerpts.
One suggested approach is to start Lipitor at a low dose (e.g., 10 mg) when combined with warfarin.
While Lipitor starting doses are described in general, there is no warfarin-specific dosing instruction in the provided excerpts.
When adding atorvastatin to warfarin, warfarin may need a 10–30% reduction.
No warfarin dose adjustment guidance is present.
Genetic factors such as CYP2C9 poor metabolizers can amplify risk when using atorvastatin with warfarin.
No pharmacogenetic/genetic testing discussion related to atorvastatin/warfarin is present.
Genetic testing is suggested if recurrent issues occur (e.g., for CYP2C9 poor metabolizers).
No genetic testing recommendation is present.
Bleeding events occur in up to 10% of unmonitored dual users of atorvastatin and warfarin, per post-marketing data.
No postmarketing incidence for atorvastatin/warfarin dual users is present in provided excerpts.
Elderly patients, patients with liver issues, or patients on multiple drugs have higher odds of bleeding with the combination.
No bleeding/warfarin-specific risk stratification is present.
In a study of more than 1,200 patients, 17% needed warfarin dose cuts after adding atorvastatin.
No such study or warfarin dose-cut statistic is present in provided excerpts.
Contradictions
Important Omissions
Warfarin-specific interaction statements (e.g., effects on warfarin exposure/INR, bleeding risk, or management such as INR monitoring frequency) are not provided in the supplied Lipitor label excerpts.
Importance:
High
Statin-to-statin interaction strength comparisons with warfarin (pravastatin/rosuvastatin/simvastatin/lovastatin/fluvastatin/pitavastatin) are not provided in the supplied excerpts.
Importance:
Moderate
Any label-supported guidance on INR targets/thresholds (e.g., INR above 4) is not present in the supplied excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple claims provide specific warfarin/INR interaction mechanisms, numeric INR changes, monitoring schedules, and bleeding incidence/dose adjustments that are not supported by the provided Lipitor label excerpts. Relying on these unverified specifics would be higher risk than only general label-supported interaction warnings.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Warfarin/INR-specific interaction, management, and comparative statin claims are not supported by the provided FDA label excerpts.
Suggested Improvement
Remove or rewrite warfarin/INR-specific numeric and monitoring claims unless directly supported by provided label text. If evaluating interactions, restrict statements to those explicitly covered in the provided label excerpt (e.g., increased myopathy risk with strong CYP3A4 inhibitors/other listed interacting drugs) and avoid INR/bleeding statistics not present in the excerpts.